NCT03515200 - Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

July 29, 2020

Study Completion Date

July 29, 2020

Conditions

Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed Remission

Interventions

DRUG

Palbociclib Oral Capsule

Given orally or nasogastrically (NG).

DRUG

Intrathecal Triple Therapy

Given intrathecally (IT).

DRUG

Dexamethasone

Given orally, nasogastrically (NG) or intravenously (IV).

DRUG

Bortezomib

Given intravenously (IV) or subcutaneously (SC).

DRUG

Dasatinib

Given orally or nasogastrically (NG).

DRUG

Doxorubicin

Given intravenously (IV).

DRUG

Ruxolitinib

Given orally or nasogastrically (NG).

Trial Locations (1)

St. Jude Children's Research Hospital, Memphis